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Radicalretropubicprostatectomy(RRP)asintendedcurativetherapyforpatientswithclinicallylocalizedprostatecancer(PC)was
initiated in 1995 in Denmark. This paper reports single-institution results from the ﬁrst 1200 consecutive patients operated during
a 15-year period. Median age at surgery was 63 years. Median PSA was 9ng/mL. Palpable tumors (≤cT2) were present in 48% of
patients. Gleason score at biopsy was ≤7 for 85% of patients. In sixty-ﬁve percent of patients, histopathology revealed localized
PCa after RRP. Positive surgical margins were found in 39.2% of the cases. Biochemical recurrence (BR) occurred for 214 (18%) of
patients. The estimated biochemical recurrence free survival (BRFS) was 71.7% and 63.2% after 5 and 10 years, respectively. When
patients were stratiﬁed according to the D’Amico criteria, BRFS after 10 years was 75.3%, 59.7%, and 39.3% for low-, medium-
and high-risk patients, respectively. In univariate analysis, clinical stage, PSA at diagnosis and type of surgery were signiﬁcant
predictors of BR. In multivariate analysis, Gleason score > 7, PSA > 10, and higher clinical stage were signiﬁcant predictors of BR.
Early Danish results in a population not subjected to screening demonstrate BRFS rates comparable with earlier reports from the
prescreening era.
1.Introduction
Radical prostatectomy for clinically localised prostate cancer
(PCa) was introduced in Denmark in 1995 [1]. Following a
slow start, the procedure is now performed in large numbers
[2]. Even though early case ﬁnding including PSA-based
screening has not been recommended, increased public
awarenessandopportunisticPSA-basedscreeninghavegrad-
ually resulted in a rising PCa incidence and a shift in stage
distribution, with increasing numbers of younger men being
diagnosed with clinically localized PCa, suitable for curative
therapy [3]. This paper presents results from the ﬁrst Danish
single-institution series focusing on biochemical recurrence-
free survival and will compare results with international
experiences according to the D’Amico risk classiﬁcation.
2.MaterialandMethods
Patients with clinically localized prostate cancer (cT1-
cT2) and a life expectancy of 10–15 years or more were
oﬀered RRP or external beam radiation therapy as curative
treatment. RRP was performed according to the method
described by Walsh et al. [4]. Robotic surgery (DaVinci) has
been performed in a limited number of cases since 2009.
Patient data have been collected prospectively in a
database. Recorded data includes clinical T-category, preop-
erative PSA, type of surgery, histopathology with Gleason
scores, and biochemical outcome. Patients have been staged
according to UICCs TNM classiﬁcation 2002 (patients from
1995–2002 were reclassiﬁed). The database is approved by
the Danish Data Protection Agency (ﬁle no.: 2006-41-6256).
Three months neoadjuvant endocrine therapy with
LHRH agonists was used routinely in all the ﬁrst 109 (9.4%)
patients. These patients are excluded when analysing ﬁnal
pathology reports. Twenty-two patients were excluded from
the analysis of biochemical failure; one patient had cT0
PCa, three patients with preoperatively veriﬁed metastatic
PC began endocrine treatment already before surgery, and
additionally 18 patients had node positive disease when2 Prostate Cancer
undergoing RRP and initiated endocrine therapy immedi-
ately following surgery.
Patients with ≤cT2a, Gleason score ≤6, PSA ≤ 10,
and no evident cancer in the apex were eligible for nerve
sparing surgical technique. The use of nerve-sparing surgery
has expanded recently for selected patients with cT1c,
unilateral PCa and Gleason score 3 + 4 = 7w h oa r en o w
oﬀered contralateral neurovascular preservation. Limited
lymphadenectomy in the obturator fossa were performed
in patients with PSA > 10 and/or Gleason score ≥ 7o r
suspect lymph nodes encountered during surgery. If node
positive disease was encountered during surgery, RRP was
not performed.
Postoperatively, all patients were followed with PSA
measurements every 3 months for one year, thereafter twice
a year for 3 years, and hereafter yearly until BR.
No patients received neither endocrine nor radiation
therapy before veriﬁed biochemical failure, deﬁned as the
ﬁrst PSA > 0.2ng/mL. Time to biochemical failure was
calculated from the date of surgery.
Uni- and multivariate analysis was used to calculate the
relative risk of biochemical recurrence according to preoper-
ative patient characteristics. Kaplan-Meier survival analysis
wasusedtocalculatethebiochemicalrecurrencefreesurvival
and log-rank test to compare risk groups. Analysis was
performed with “Medcalc” (Belgium). Results are reported
as median and range. P values<.05 is considered signiﬁcant.
3. Results
PatientcharacteristicsareshowninTable1.Medianfollowup
was 4yrs. Median age at surgery was 63yrs (Range 45–
76yrs). Median age has risen signiﬁcantly from 63 to 65yrs
through the period (P<. 0001). Clinically localized PC
was present in 1166 (97.3%) patients. One patient with
elevated PSA and a massive family history of PC opted
for surgery even though repeated biopsies were normal.
Final histopathology veriﬁed the presence of a Gleason
6 PC in this patient. In 3 of 33 cases with suspected
clinically extracapsular extension, metastatic PC had been
documented, but RRP was performed RP as part of a
debulking procedure.
Prostate volume assessed by transrectal ultrasound
(TRUS) was available in 578 patients (48%) and the median
volume was 39mL (15–150mL).
Median preoperative PSA was 9 (0.4–218) (ng/mL)
(Table 1). A signiﬁcant decrease in preoperative PSA (P<
.001) over time has been found (data not shown).
Gleason score at biopsy was not available for 123 patients
(10.3%) either because they were graded using the WHO
system, or the focus was too small for Gleason grading.
Thirty-six procedures (3%) were robotic-assisted RP
performed by one surgeon One surgeon performed more
than half (635/52.5%) of the open RRPs, while 5 diﬀerent
surgeons carried out the remainder.
One fourth of all cases (24.4%) underwent nerve-sparing
RP. Lymphadenectomy was performed in 682 (57%) of all
patients. At ﬁnal pathology, 771 (64.3%) had pathological
conﬁrmation of organ conﬁned PCa, whereas 307 patients
Table 1: Preoperative patient characteristics.
Median Range %
Age years 63 45–76
TRUS volume/mL (N = 578) 39 15–150
PSA (N = 1198) 9 0.4–218
PSA ≤ 48 . 9
PSA 4.1–10 51.6
PSA 10. 1–20 30.6
PSA ≥ 20 8.9
cT category N %
T0 1 0.1
T1a/b 35 2.9
T1c 588 49.0
T2a/b 543 45.3
T3a 33 2.7
Gleason score
≤5 154 12.8
6 432 36.0
7 434 36.2
≥85 7 4 . 8
N/A† 123 10.2
Lymphadenectomy
Yes 682 57
No 518 43
Surgical method
Unilateral NS 244 20.4
Bilateral NS 53 4.4
Non nerve sparing 903 75.2
†N/A = not available (see text).
Overall BRFS
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Figure 1: Excluding pT4, pN+, and cT0 patients.
(25.5%) were found to have extracapsular tumour extension
(Table 2).
Biochemical recurrence occurred for 214 (18%) of
evaluatedpatients.Inunivariateanalysis,PSA > 10and>cT2
was associated with a signiﬁcant increased relative risk of
biochemical recurrence (BR). Surprisingly, increasing biopsyProstate Cancer 3
Table 2: Histopathological data.
Median Range
Prostate weight. grams (n = 1024) 46 18–236
pT category N %
pT0 6 0.5
pT2 a/b/c 771 64.3
pT3a 196 16.4
pT3b 110 9.1
pT4 3 0.3
N/A† 113 9.4
pN category
N0 566 47.2
N1 18 1.5
Nx 503 41.9
N/A† 113 9.4
pM category
M0 833 69.4
M1 3 0.3
Mx 251 20.9
N/A† 113 9.4
Margins
Positive 470 39.2
Negative 617 51.4
N/A† 113 9.4
Specien Gleason score ≤56 6 5 . 5
6 278 23.2
7 638 53.2
≥87 2 6 . 0
N/A† 146 12.2
†N/A = not available (see text).
Gleason scores was not found to be associated with increased
risk of BR in univariate analysis. Patients who underwent
nervesparing surgical technique had reduced risk of BR. In
Cox multiple hazard regression, PSA > 10, Gleason score 8–
10 and ≥cT2 were all associated with a signiﬁcant risk of BR,
whereasageandsurgicaltechniquehadnosigniﬁcantimpact
(Table 4).
The Kaplan-Meier estimate of biochemical recurrence-
free survival (BRFS) was 71.7% and 63.2% after 5 and 10
years, respectively, Figure 1. When patients were stratiﬁed
according to the to the D’Amico criteria, BRFS after 10 years
was 75.3%, 59.7%, and 39.3% for low-, medium- and high-
risk patients, respectively, Figure 2. There was a statistically
signiﬁcant diﬀerence for the risk of BR between each group.
4. Discussion
This paper is the ﬁrstDanish report on biochemical outcome
for patients surgically treated for localized prostate cancer. In
Denmark, the approach to curative treatment for localized
PCahasbeenconservative,untilearlyresultsfromtheSPCG-
4 study reported a signiﬁcant survival beneﬁt in favour of
radical prostatectomy compared to watchful waiting [5].
Table 3: Uni- and multivariate analysis. Risk of biochemical
recurrence.
RR 95% CI P-value
PSA
PSA ≤ 4 0.7 0.4–1.3 .25
PSA 4.1–10 1
PSA 10, 1–20 1.7 1.3–2.3 .0001
PSA ≥ 20 3 2.2–4.1 <.0001
cT-category
T1a/b 1,6 0.8–3.1 .2
T1c 1
T2a/b 1.9 1.4–2.4 <.0001
T3a 3.1 1.9–5.0 <.0001
cT0 excluded (N = 1)
Biopsy Gleason score
≤51
6 0.8 0.6–1.2 .3
7 0.8 0.5–1.1 .2
≥8 1.1 0.7–1.7 .7
N/A = 123
Age
<56 0.9 0.6–1.4 .9
56–65 1
>65 0.9 0.7–1.2 .4
Surgical method
Unilateral NS 0.5 0.4–0.8 .002
Bilateral NS 0.6 0.3–1.3 .2
Non nerve sparing 1
† N/A= not available (see text).
Table 4: Cox multiple regression hazard analysis.
OR 95% CI P-value
Age not signiﬁcant
Surgical technique not signiﬁcant
PSA
PSA ≤ 4 not signiﬁcant
PSA 4.1–10 1
PSA 10, 1–20 1.7 1.2–2.3 .0011
PSA ≥ 20 2.8 1.9–4.2 <.0001
Biopsy Gleason score
≤51
6 not signiﬁcant
7 not signiﬁcant
8–10 3.7 2.4–5.6 <0001
GS N/A excluded
cT-category
T1a/b not signiﬁcant
T1c 1
T2a/b 1.6 1.2–2.2 .0014
T3a 2.6 1.5–5.6 .00344 Prostate Cancer
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Figure 2: Excluding pT4, pN+ and cT0 patients.
As a consequence of this approach, PSA-based screening is
not recommended in Denmark. This strategy is reﬂected
in the distribution of clinical T-category where almost half
of the patients had palpable tumours at diagnosis. This
is comparable to other prescreening studies [6–8]. PSA
screening will lead to stage migration and modern series
often report more than 60% nonpalpable tumours [9].
Median age at RRP has increased, mainly as a conse-
quence of change in treatment strategy as patients >65 years
were not oﬀered RRP when the treatment was initiated.
Median PSA was 9ng/mL. The median PSA is higher
than the comparable reports from the prescreening era. Hull
et al. reported a median PSA of 6.8ng/mL and Boorjian et
al. a median PSA of 6.5ng/mL [10, 11]. In papers where
the median PSA is not reported, but the PSA distribution
is listed, our patient material also had a lower percentage of
patients with PSA < 10ng/mL [7, 8, 11, 12].
The distribution of biopsy Gleason scores in our series
alsodiﬀersfromD’Amicoetal.’spaperfrom1998where77%
of patients had Gleason scores ≤6[ 12]. The same distribu-
tion is comparable to other contemporary American reports
[9–11, 13]. We had 48.2% patients with Gleason scores ≤
6. This is likely to aﬀect the biochemical recurrence rate,
especially for the low risk group, and another indicator that
our patients had a higher tumour burden than comparable
series.
Early reports indicated that neoadjuvant hormonal ther-
apy reduced blood loss, biochemical failure, and positive
margin rates after surgery [14, 15]. As later results could
not demonstrate any diﬀerence on biochemical failure
rates [16], neoadjuvant hormonal therapy was abandoned.
Neoadjuvant hormonal therapy inﬂuences the assessment
of ﬁnal histopathology [17]. Therefore, these patients in
our series have been excluded from analysis of pT and pN
categories as well as positive margins.
One fourth of our patients had locally advanced disease
on ﬁnal histopathology. Studies from the prescreening era
with comparable preoperative patient characteristics have
reported the same rate of extracapsular extension and/or
locally advanced PCa [6, 18].
As it appears from the cT-category distribution and
median preoperative PSA, the patients in our material must
be expected to have a higher risk of positive margins than
encountered in the reports quoted above. The high rate of
positive margins in our series is of concern. A larger tumour
burden in this ﬁrst reported Danish cohort may explain part
of this. However, a critical revision of the surgical technique
is ongoing, including a meticulous analysis of location and
extent of margins and its inﬂuence on outcome.
Nerve sparingsurgeryhasbeencarriedoutinonly24.8%
of patients. Univariate analysis showed a decreased relative
risk of BR. This is an indicator of a correct selection of
patients.
In our series, lymphadectomy (LND) was performed
according to the patients’ preoperative characteristics. In
spite of our high rate of LNDs we continue to have low
and acceptable 30-day morbidity. Moreover, our in-hospital
admittance has declined signiﬁcantly over time from a
median of 7 days to currently 3 days [19].
D’Amico risk classiﬁcation is a model based on pre-
treatment PSA, biopsy Gleason score, and T-category that
predicts the risk of BRFS after deﬁnitive prostate cancer
treatment. It is important to remember that patients in each
risk group have a certain degree of heterogeneity, but the risk
stratiﬁcation has been validated, even in the PSA screening
era [9, 10, 20].
In the original paper from 1998 [12], D’Amico et al.
reported a 5-year BRFS after RRP of 85%, 60%, and 30%
for low, intermediate, and high-risk groups, respectively. A
later update in 2001 reported the 10-year BRFS of 83%, 46%
and 29% for the same groups [21]. Boorjian et al. reported
a 10-year BRFS of 82%, 65%, and 55% with patients treated
primarily in the PSA screening era [10]. As Hernandez et al.
showedin2007,PSAscreeningaﬀectstheBRFSoutcomedue
to stage migration, lead-time, and lengh-time bias [9]. We
report an estimated 10-year BRFS rate of 75.3%, 59.7%, and
39.3%.
The reported diﬀerences within each risk group must
be regarded with caution. Diﬀerences in deﬁnition of PSA
failure obviously aﬀect the biochemical recurrence rate. We
used the ﬁrst occurrence of a PSA > 0.2ng/mL as criterion
for failure, whereas patients in the D’Amico paper had to
have three consecutive rises in PSA > 0.2ng/mL., likely
to postpone the BR occurrence. This was later revised to
the second PSA > 0.2ng/mL [22]. Boorjian et al. used
PSA > 0.4ng/mL as a criterion of failure [10, 12, 21].
Selection of patients also is of great importance. In a
screening scenario, the outcome in the low-risk group will be
inﬂuenced by large numbers of patients with small tumours
and possibly insigniﬁcant tumours, whereas the distribution
of risk factors in the high risk group may be aﬀected by a
treatment policy where patients with poor risk factors are
oﬀered radiotherapy [9, 10, 21].
Multivariate analysis of our patients conﬁrmed the
results from the D’Amico paper. We found that patients
classiﬁed as intermediate or high risk had signiﬁcantly
increased odds of BR.Prostate Cancer 5
In contemporary series, positive margin rates have
dropped to 10% in centres of excellence [9, 11]. Although
the distribution of T-categories, biopsy Gleason scores, and
pretreatment PSA indicates a larger tumour volume when
compared to contemporary series from countries where
radical prostatectomy has been performed for much longer,
thismayactuallybeanunderestimationofthetruediﬀerence
in biological potential. While the high rate of positive
margins in our series is of concern, it is of interest, in
continuation of the speculations above, to compare the
margin rates from older American series: Boorjian et al. had
a positive surgical margin rate of 33%, Bill-Axelson et al.
35.3%, and Blute et al. 34% [7, 10, 18].
5. Conclusion
Our series represent the ﬁrst large cohort of patients
undergoing radical prostatectomy for clinically localised PCa
in a country where almost no deﬁnitive therapy for prostate
cancer has been practised before.
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